Drug-related Risk of Severe Hypoglycaemia in Observational Studies: a Systematic Review and Meta-analysis

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2015 Oct 14

PMID 26458540

Citations 5

Authors

Marcin Czech

Elzbieta Rdzanek

Justyna Paweska

Olga Adamowicz-Sidor

Maciej Niewada

Michal Jakubczyk

Affiliations

Soon will be listed here.

Abstract

Background: Diabetes mellitus (DM) leads to multiple complications, including severe hypoglycaemia events (SHEs). SHEs can impact a patient's quality of life and compliance and may directly result in additional costs to the health care system. The aim of this review was to evaluate the risk of severe hypoglycaemia in patients with type 1 (T1) and 2 (T2) DM as observed in everyday clinical practice for various drug regimens.

Methods: We conducted a systematic review of observational (retrospective or prospective) studies in the MEDLINE, Embase, and Cochrane Library databases that covered at least 100 children or adults with T1/T2 DM. In T1 DM, basal-bolus/pre-mix insulin (human or analogue) and insulin pump were reviewed, and in T2 DM, basal-bolus/pre-mix insulin (human or analogue), oral antidiabetic drugs supported with basal insulin (human or analogue), sulfonylureas in monotherapy, and combined oral treatment were reviewed. In order to estimate SHE rates, we extracted data on the time horizon of the study, number of patients, number of SHEs, and number of patients experiencing at least one SHE. We used a random effects model to estimate the annual SHE rate. We considered the risk for other antidiabetic medications in T2 DM to be negligible and the results of our main review yielded no observational data for premixes in T1 DM so they were assessed based on relative rates taken from additional systematic reviews. The study, being a desk research, did not involve any human subjects (including human material or human data) and no ethical committee approval was asked for. For the same reason there was no need to collect informed consent for participation in the study.

Results: We identified 76 observational studies encompassing 707,722.30 patient-years. The estimated annual SHE rate varied from 0.168 (95 % CI 0.123-0.237) for insulin pump up to 1.628 for biphasic human insulin in T1 DM patients, and from 0.0035 for oral antidiabetic drugs up to 0.554 (95 % CI 0.157-7.534) for basal-bolus with human insulin in T2 DM patients.

Conclusions: Our review indicates that SHE rates differ between patients depending on treatment regimen. However, SHEs are also driven by other factors. Proper modelling techniques are needed to use various types of information in published studies.

Citing Articles

Investigation of Severe Hypoglycemia Risk Among Patients with Diabetes Treated with Ultra-Rapid Lispro in Japan.

Mizuno S, Minatoya M, Osaga S, Chin R, Imori M Adv Ther. 2024; 42(1):413-426.

PMID: 39570544 PMC: 11782313. DOI: 10.1007/s12325-024-03050-1.

Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.

Pohlmann J, Mitchell B, Bajpai S, Osumili B, Valentine W J Diabetes Sci Technol. 2019; 13(5):910-918.

PMID: 30700165 PMC: 6955465. DOI: 10.1177/1932296819826577.

Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study.

Agarwal P, Jindal C, Sapakal V Indian J Endocrinol Metab. 2018; 22(1):41-46.

PMID: 29535935 PMC: 5838908. DOI: 10.4103/ijem.IJEM_97_16.

Reversal of Early Diabetic Nephropathy by Islet Transplantation under the Kidney Capsule in a Rat Model.

He Y, Xu Z, Zhou M, Wu M, Chen X, Wang S J Diabetes Res. 2016; 2016:4157313.

PMID: 27725943 PMC: 5048050. DOI: 10.1155/2016/4157313.

Czech M, Rdzanek E, Paweska J, Adamowicz-Sidor O, Niewada M, Jakubczyk M BMC Endocr Disord. 2015; 15:57.

PMID: 26458540 PMC: 4603823. DOI: 10.1186/s12902-015-0052-z.

References

Valensi P, Shaban J, Benroubi M, Kawamori R, Borzi V, Shah S . Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study. Curr Med Res Opin. 2013; 29(6):601-9. DOI: 10.1185/03007995.2013.786692. View

Hartemann-Heurtier A, Sachon C, Masseboeuf N, Corset E, Grimaldi A . Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycemia. An observational cohort study. Diabetes Metab. 2003; 29(1):53-7. DOI: 10.1016/s1262-3636(07)70007-1. View

Shah S, Das A, Kumar A, Unnikrishnan A, Kalra S, Baruah M . Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes. Adv Ther. 2009; 26(3):325-35. DOI: 10.1007/s12325-009-0006-9. View

Dornhorst A, Luddeke H, Honka M, Ackermann R, Merilainen M, Gallwitz B . Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin. 2007; 24(2):369-76. DOI: 10.1185/030079908x260835. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Lezzar A, Ayad F, Dahaoui A, Salah-Mansour A, Berrouiguet A . Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study. Diabetes Res Clin Pract. 2013; 101 Suppl 1:S37-44. DOI: 10.1016/S0168-8227(13)70017-2. View

Ishii H, Iwase M, Seino H, Shuto Y, Atsumi Y . Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan. Curr Med Res Opin. 2011; 27(3):643-50. DOI: 10.1185/03007995.2010.551760. View

Hermansen K, Lund P, Clemmensen K, Breum L, Moller M, Rosenfalck A . 3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study. Rev Diabet Stud. 2007; 4(2):89-97. PMC: 2036264. DOI: 10.1900/RDS.2007.4.89. View

Scheidegger U, Allemann S, Scheidegger K, Diem P . Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Med Wkly. 2007; 137(33-34):476-82. DOI: 10.4414/smw.2007.11588. View

10.

Zilov A, El Naggar N, Shah S, Shen C, Haddad J . Insulin detemir in the management of type 2 diabetes in non-Western countries: safety and effectiveness data from the A₁chieve observational study. Diabetes Res Clin Pract. 2013; 101(3):317-25. DOI: 10.1016/j.diabres.2013.06.003. View

11.

Pinelli N, Hurren K . Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother. 2011; 45(7-8):850-60. DOI: 10.1345/aph.1Q024. View

12.

Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

13.

Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A . Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database. Diabetes Metab Res Rev. 2013; 30(5):395-404. DOI: 10.1002/dmrr.2500. View

14.

Hermansen K, Dornhorst A, Sreenan S . Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Curr Med Res Opin. 2009; 25(11):2601-8. DOI: 10.1185/03007990903262885. View

15.

El-Naggar N, Almansari A, Khudada K, Salman S, Mariswamy N, AbdelFattah W . The A1 chieve study - an observational non-interventional study of patients with type 2 diabetes mellitus initiating or switched to insulin analogue therapy: subgroup analysis of the Gulf population. Int J Clin Pract. 2013; 67(2):128-38. DOI: 10.1111/ijcp.12078. View

16.

Gangji A, Cukierman T, Gerstein H, Goldsmith C, Clase C . A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007; 30(2):389-94. DOI: 10.2337/dc06-1789. View

17.

Gao Y, Guo X, Vaz J . Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diabetes Obes Metab. 2008; 11(1):33-40. DOI: 10.1111/j.1463-1326.2008.00904.x. View

18.

Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A . Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. Expert Opin Pharmacother. 2011; 12(16):2449-55. DOI: 10.1517/14656566.2011.626766. View

19.

Jang H, Guler S, Shestakova M . When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008; 62(7):1013-8. PMC: 2438599. DOI: 10.1111/j.1742-1241.2008.01792.x. View

20.

Malek R, Arbouche Z, Bachaoui M, Zinai S, Dahaoui A, Senoussaoui S . Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study. Diabetes Res Clin Pract. 2013; 101 Suppl 1:S45-9. DOI: 10.1016/S0168-8227(13)70018-4. View